comparemela.com

Page 11 - Stevene Nissen News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Statin-intolerant patients can use bempedoic acid: Cleveland

The use of bempedoic acid (a cholesterol-lowering drug) in statin-intolerant patients lowered low-density lipoprotein (LDL) cholesterol and reduced heart attacks and coronary procedures.

Stevene nissenAmerican college of cardiologyDrug administrationHeart vascular thoracic institute at cleveland clinicDr nissen tradearabia news serviceCleveland clinicLate breaking science sessionAmerican collegeAnnual scientific sessionNew orleansNew england journalHeart vascularThoracic instituteArabia newsRade arabiaIddle east trade news

Newer drug may be an alternative to help lower heart disease risk, study finds

A newer drug may help lower heart disease risk, according to a study.

United statesStevene nissenHoward weintraubNew england journalDrug administration approved

Newer drug may be an alternative to help lower heart disease risk, study finds

Newer drug may be an alternative to help lower heart disease risk, study finds
mycentraloregon.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from mycentraloregon.com Daily Mail and Mail on Sunday newspapers.

United statesStevene nissenHoward weintraubNew england journalDrug administration approved

Newer drug may be an alternative to help lower heart disease risk, study finds - WEIS | Local & Area News, Sports, & Weather

(NEW YORK) Statins, drugs that are used to lower one's cholesterol, can save lives - but come with steep side effects for up to a third of people who need them. Now, a new study shows an alternative drug can also dramatically reduce heart disease risk. The study in The New England Journal of Medicine

United statesStevene nissenHoward weintraubNew england journalDrug administration approved

Bempedoic acid an effective alternative for statin-intolerant patients: CLEAR Outcomes

NEW ORLEANS — In the CLEAR Outcomes trial, bempedoic acid reduced risk for major CV events by 13% compared with placebo, including a 23% lower risk for MI, among adults with a history of CVD or at high risk deemed statin intolerant.Bempedoic acid (Nexletol, Esperion Therapeutics) was FDA approved in 2020 for lowering LDL, but the effects of the drug on CV outcomes have not been assessed,

United statesKatie kalvaitisStevene nissenEli lillyJohnf keaney jrRegina schafferPatricia dickeyJohnh alexanderHoward weintraubByregina schafferDuke university school of medicineDuke clinical research instituteUniversity of massachusetts medical school in worcesterConvention center bempedoicAmerican college of cardiology scientific sessionVascular thoracic institute

vimarsana © 2020. All Rights Reserved.